Coherus Oncology, Inc. (CHRS)

1.41USD -3.42% (-0.05)

Over 1M: +0.0%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

1.2 1.3 1.4 1.5
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Operating Cash Flow: -54.3M Q3 '23 — Free Cash Flow: -54.3M Q4 '23 — Operating Cash Flow: -12.9M Q4 '23 — Free Cash Flow: -13M Q1 '24 — Operating Cash Flow: -46.8M Q2 '24 — Operating Cash Flow: 59.7M Q3 '24 — Operating Cash Flow: -62M Q4 '24 — Operating Cash Flow: 28.6M Q1 '25 — Operating Cash Flow: -25.8M Q2 '25 — Operating Cash Flow: -46.6M Q3 '25 — Operating Cash Flow: -46.3M Q4 '25 — Operating Cash Flow: -19.7M Q1 '26 — Operating Cash Flow: -57.9M Q2 '26 — Operating Cash Flow: -62.1M -50M -25M 0 25M 50M 75M
Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Operating Cash Flow Free Cash Flow

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 62 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.9
SBC / sales 21.9%
OE margin -387.1%
Oper. margin -311.6%
Gross margin 68.9%
Accruals 28.2%
EBITDA margin -304.5%
FCF margin -365.2%
OCF margin -365.2%
Profit margin -259.4%
ROA -69.1%
ROCE -137.2%
ROE -217.2%
Capex / sales —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

5.7
EV/Sales 2.2×
EV/OE -0.57×
P/C 2.1×
P/B 3.6×
FCF yield -85.4%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

5.0
ND/EBITDA 0.94
Interest cover -17.5×
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 1.7×
F-score 5.6 pts
Cash runway 0.57 yr
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.6
Sales/sh Y/Y +57.4%
Sales CAGR 4Y -40.1%
Sales Q/Q +39.5%
EPS Y/Y -171.9%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.